CYP19A1 and Urinary incontinence: The association was negative and statistically significant for aromatase inhibitor therapy (HR = 0.71; 95% CI: 0.66–0.78) as compared to women without endocrine therapy, whereas tamoxifen therapy was not associated with decreased or increased urinary incontinence risk.